Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orient Europharma CoROCO:4120 +0.91%60 Dividend Yield % is 9.09% as of Jul. 22, 2026, which is 193% above its 10-year median of 3.10. GuruFocus rates ROCO:4120 with a GF Score™ of 60/100 and a GF Value™ of NT$44.98 (Fairly Valued). The stock has 4 warning signs investors should review. Among 513 Drug Manufacturers companies, Orient Europharma Co ranks better than 52.63% on this metric.
As of today (2026-07-22), the Trailing Annual Dividend Yield of Orient Europharma Co is 9.09%.
Warning Sign:
Orient Europharma Co Ltd stock Dividend Yield % is close to 1-year low.
The historical rank and industry rank for Orient Europharma Co's Dividend Yield % or its related term are showing as below:
ROCO:4120'
s Dividend Yield % Range Over the Past 10 Years
Min: 1.74 Med: 3.1 Max: 9.09
Current: 9.09
During the past 13 years, the highest Dividend Yield of Orient Europharma Co was 9.09%. The lowest was 1.74%. And the median was 3.10%.
ROCO:4120's Dividend Yield % is ranked better than 52.63% of 513
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs ROCO:4120: 9.09
During the past 3 years, the average Dividends Per Share Growth Rate was 5.60% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Orient Europharma Co was 72.20% per year. The lowest was -22.10% per year. And the median was 2.50% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Orient Europharma Co (ROCO:4120) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Orient Europharma Co Dividend Yield % Related Terms
Orient Europharma Co Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Orient Europharma Co's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4120 vs ZTS, UTHR: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Europharma Co's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Europharma Co Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Europharma Co's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Orient Europharma Co's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Orient Europharma Co Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
TWD 4.000000
2026-07-20
2026-07-21
2026-08-06
Cash Dividend
annually
TWD:TWD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Orient Europharma Co's Trailing Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Europharma Co (ROCO:4120) has a Dividend Yield % of 9.09% as of Jul. 22, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Orient Europharma Co and its competitors. This is 193% above median its historical median of 3.10. Over the past decade, Orient Europharma Co's Dividend Yield % has ranged from 1.74 to 9.09. According to the industry distribution chart, Orient Europharma Co ranks #243 out of 513 companies in the Drug Manufacturers industry, placing it in the top 47.4%.
Is Orient Europharma Co's Dividend Yield % too high?
Orient Europharma Co's current Dividend Yield % of 9.09% is 193% above median its 10-year median of 3.10. Over the past 10 years, this metric has ranged from a low of 1.74 to a high of 9.09. The Drug Manufacturers industry median Dividend Yield % is 1.92. Orient Europharma Co's value of 9.09% is 373.4% above this industry median. Based on the distribution chart, Orient Europharma Co ranks #243 out of 513 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orient Europharma Co has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orient Europharma Co's Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Europharma Co ranks #243 out of 513 companies for Dividend Yield %. This puts Orient Europharma Co in the upper half of its industry. The industry median Dividend Yield % is 1.92. Orient Europharma Co's value of 9.09% is 373.4% above this benchmark. Historically, Orient Europharma Co's own Dividend Yield % has ranged from 1.74 to 9.09 over the past decade. While the company's 10-year median is 3.10 vs. the industry median of 1.92, Orient Europharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.92, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Europharma Co's current Dividend Yield % of 9.09% is 373.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Orient Europharma Co and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Europharma Co's current Dividend Yield % is 9.09%, which is 193% above median its own 10-year median of 3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Europharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Europharma Co (ROCO:4120) is currently considered Fairly Valued. The stock's GF Value™ is NT$44.98, compared to a current price of NT$44.40 — trading 1.3% below its estimated fair value. The current Dividend Yield % is 9.09%, which is 193% above median its 10-year median of 3.10 and 373.4% above the Drug Manufacturers industry median of 1.92. Orient Europharma Co's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Orient Europharma Co (ROCO:4120), the current Dividend Yield % is 9.09% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued.
The current stock price of NT$44.40 is trading 1.3% below its estimated GF Value™ of NT$44.98.
GuruFocus considers Orient Europharma Co to be Fairly Valued.
Key valuation signals for ROCO:4120:
Dividend Yield %: 9.09% (193% above median its 10-year median of 3.10)
GF Value™: NT$44.98 vs. price of NT$44.40 (1.3% below fair value)
Industry Position: 373.4% above the Drug Manufacturers median (#243 of 513)
No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
60GF Score
Get the complete analysis for ROCO:4120
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4120 has been successfully added to your 
